Atherosclerotic Cardiovascular Disease (ASCVD) is a long-term, progressive condition that impacts multiple arteries throughout the body, such as the coronary arteries (heart), cerebral arteries (brain), and peripheral arteries (legs). The most common types of ASCVD include coronary artery disease (CAD), cerebrovascular disorders like stroke, and peripheral arterial disease (PAD).
Several risk factors contribute to the onset and progression of ASCVD. These include unhealthy eating habits, sedentary lifestyle, tobacco use, obesity, genetic predisposition, and excessive alcohol intake. During its early stages, ASCVD might not cause noticeable symptoms. However, as the disease advances and blood flow becomes restricted due to plaque buildup, symptoms like chest pain, fatigue, dizziness, cold sweats, palpitations, and shortness of breath start to appear—varying based on which artery is affected.
📊 Check out this engaging visual to understand ASCVD trends and data:
👉 View ASCVD Infographic
Epidemiological Insights for ASCVD (2020–2034)
The epidemiological analysis of ASCVD in the seven major markets (7MM)—including the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan—covers several key segments:
Overall diagnosed prevalent population
Gender-wise distribution
Age-specific prevalence
Prevalence by comorbid conditions
In 2023, the total diagnosed prevalent cases of ASCVD across the 7MM stood at roughly 55.7 million. The United States had the highest share with approximately 26 million cases. Within Europe, Germany recorded about 5 million diagnosed individuals, followed by France with 4 million and Spain with 3 million. Japan accounted for around 8 million cases, contributing nearly 15% of the total.
When broken down by comorbidities, the most prevalent was other coronary heart diseases (CHD), amounting to 28 million cases. Other significant coexisting conditions include acute coronary syndrome (ACS), ischemic stroke, peripheral artery disease (PAD), and chronic kidney disease (CKD).
Gender-specific data from the EU4 and the UK indicate a higher number of males (12 million) diagnosed with ASCVD compared to females (8 million).
🧬 For more detailed epidemiological data and analysis, refer to the complete report here:
👉 Access ASCVD Market Report
ASCVD Market Landscape
In 2023, the estimated size of the ASCVD market across the 7MM was approximately USD 23 billion. With increasing disease prevalence and innovation in treatments, the market is expected to witness significant expansion.
Key Market Drivers
Well-defined clinical guidelines help streamline the diagnosis and treatment process, supporting the growth of therapeutic solutions.
The absence of approved therapies for lowering lipoprotein(a) [Lp(a)] offers substantial room for innovation and market penetration.
Market Challenges
Many patients struggle to follow long-term medication regimens and adopt lifestyle changes, which hinders treatment efficacy.
Regulatory complexities can slow down the approval of novel drugs and devices, affecting market momentum.
📈 Gain a deeper understanding of the market drivers and barriers through this visual summary:
👉 Explore ASCVD Market Trends
Promising Therapies in the Pipeline
The ASCVD treatment landscape is evolving with several novel therapies under investigation:
🔬 Olpasiran – An RNA interference therapy targeting Lp(a), developed by Amgen Inc.
💊 Obicetrapib – A CETP inhibitor aimed at improving lipid profiles, in development by NewAmsterdam Pharma
Other candidates in various phases of clinical trials
Leading companies shaping the ASCVD pipeline include:
Amgen Inc.
Merck Sharp & Dohme Corp.
NewAmsterdam Pharma
🔍 Explore more about these emerging therapies and the top players in the field by accessing the detailed market intelligence here:
👉 Discover ASCVD Therapeutic Pipeline